Dr. John Cush RheumNow
3 years 4 months ago
PJP Prophylaxis Needed with Steroids and RTX
The 2023 EULAR Vasculitis guidelines recommends primary prophylaxis with antibiotics, especially in rheumatic disease patients receiving RTX.
https://t.co/eq42bK7MB1 https://t.co/Wk1hOpXanv
Dr. Rachel Tate uptoTate
3 years 4 months ago
I want to thank all of our amazing contributors for @RheumNow’s Women in Rheumatology: The XX Factor month. @KDAO2011 @gwenesta_melton and I agree that the future looks brighter when we come together as a community.
Dr. John Cush RheumNow
3 years 4 months ago
RheumThoughts: Giving Good Care in Diversity takes Time
Dr. Yvonne Sherrer and second-year fellow Dr. Corin Agoris discuss a case where extended time led to improved patient outcomes.
https://t.co/j4QvtBCy6n https://t.co/kECx0yLqJg
Dr. John Cush RheumNow
3 years 4 months ago
Stop RA trail:
Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 @RheumNow https://t.co/0uQshODl1j https://t.co/sXIYyQeemJ
Dr. John Cush RheumNow
3 years 4 months ago
#RNL2023 @RheumNow
There are a lot of RA Rx on market now - do we need more?
Dr. Brenner: YES
Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/xavJrFX84G https://t.co/gAdMU4AgXz
Dr. John Cush RheumNow
3 years 4 months ago
Dr Brenner at #RNL2023
Excellent description on how fibroblasts are major producers of IL-6 producers
Clinically presents a target for blocking the fibroblasts, upstream the inflammatory cascade in RA
@RheumNow https://t.co/9eQDkEzLBS https://t.co/nOGsjJH7AI
Women with systemic lupus erythematosus (SLE) had higher risks for maternal and fetal morbidity compared to those without the chronic autoimmune disorder, according to a nationwide analysis of U.S. data.
Dr. John Cush RheumNow
3 years 4 months ago
5 year retrospective study of hip replacements (w/ RA, PsA, OA, AS pts), looked at those w perioperative TNFi vs stopped TNFi; showing no differences in outcomes (p = 0.713)> @ last F/U, revision rates were TNFi 2.5%, nonbiologics 3% & 0.8% OA THAs https://t.co/fMKJLyMO6A https://t.co/FofBlxmNEt
Dr. John Cush RheumNow
3 years 4 months ago
#RNL2023 @RheumNow
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/WNqQ8HVP9n https://t.co/qWYLoMWELv
Dr. John Cush RheumNow
3 years 4 months ago
JAKi cycling, likely something we all do/consider in clinic. Dr. S. Cohen reviews the JAK-pot study which shows good, expected results between cycling in patients. #RNL2023 @RheumNow https://t.co/72m0GnmBkZ https://t.co/IThonRjpWD
Dr. John Cush RheumNow
3 years 4 months ago
How do you prevent RA in at-risk patient?
Smoking cessation! Healthy weight and exercise! Diet! Periodontal health! 🚭🏋️🥕🦷
Education follow-up!
Not robustly proven to prevent/delay RA, but may be more important than early DMARD intervention! Kevin Deane, MD
#RNL2023
Dr. John Cush RheumNow
3 years 4 months ago
Korean retrospective claims analysis of #RA (n=54 .7K; 39K RF/CCP+) (2010-2019; F/U 4.3 yrs) saw Parkinsons dx in 290 RA; Compared to controls, RA had a significant 1.74-fold higher risk of PD (found in seropos HR 1.95) but not seroneg RA https://t.co/GRahCXDuYt https://t.co/ohWK51frFr
On the final day of ACR 2023 State of the Art Conference, Dr. Paul Cremer reviewed pericarditis management. Dr. Cremer, a cardiologist at the Cleveland Clinic Foundation, reviewed the questions patients ask about pericarditis including why the disease develops, will it recur, how is it treated, and what will their treatment duration be.
